Phase I trial of CArbonic Anhydrase Inhibition in combination with radiochemotherapy or radioimmunotherapy in small cell lung carcinoma (ICAR) - ICAR

Centre Antoine Lacassagne0 sites40 target enrollmentStarted: December 22, 2022Last updated: August 21, 2024

Conditions

Trial Snapshot

No summary available.

•Age greater than or equal to 18 years,, for extended CPC Patient with histologically proven CPC, not localised to the chest,, for extended CPC Patient eligible for first line chemoimmunotherapy,, for extended CPC Patient who has received at least 1 cycle of chemoimmunotherapy (maximum 4 cycles) with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as first treatment for their extended CPC, for extended CPC Patient responds or is stable according to RECIST 1.1 criteria and/or PERCIST 1.0 criteria after platinum-based chemoimmunotherapy, etoposide and immunotherapy (atezolizumab or durvalumab), Performance Status 0 to 2,, Measurable lesion according to RECIST 1.1 criteria and/or PERCIST 1.0 criteria, If the patient is a woman of childbearing age, she must be surgically sterile or agree to use two adequate methods of contraception, If the male patient has one or more female partners of childbearing age, he must agree to use an adequate method of contraception, Patient affiliated to a social security scheme, for localized CPC : Patient with histologically proven CPC, located in the chest, non-metastatic, for localized CPC : Treatment-naive patient with localized CPC, for localized CPC : Patient to be started on radiotherapy combined with platinum-based chemotherapy and etoposide

•Previous thoracic irradiation or near/in the thoracic irradiation field, without possible re-irradiation, Contraindication to thoracic radiotherapy treatment: unbalanced congestive heart failure (ejection fraction < 30%, clinical signs), severe respiratory failure, Vulnerable persons, for localized CPC : Patient with metastatic disease

Sponsor